Bayer: Peripheral Arterial Disease trials
The registry lists 10 Peripheral Arterial Disease studies with Bayer as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 1Phase 2 1Phase 3 3No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower ExtremitiesCompletedNCT02504216Phase 3Results posted
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery DiseaseCompletedNCT01776424Phase 3Results posted
- An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their LegsCompletedNCT07142655
- A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French PatientsCompletedNCT04824729
- A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the LegsCompletedNCT04401761
- Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic AcidCompletedNCT03746275
- Iloprost Therapy in Patients With Critical Limb IschemiaCompletedNCT01458041
- Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive DiseaseCompletedNCT01007578Phase 1
- Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance AngiographyCompletedNCT00652418Phase 2
- Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery DiseaseCompletedNCT00296855Phase 3